Abstracts tagged "Biomarkers"

Abstract Number: 1774 • ACR Convergence 2023
Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease
José Lisbona-Montañez¹, Patricia Ruiz-Limon², Arkaitz Mucientes³, Natalia Mena Vazquez⁴, Isabel Moreno-Indias³, SARA MANRIQUE⁵, Laura Cano-García⁶, Rocío Redondo-Rodríguez⁶, Francisco J tinahones³ and Antonio Fernandez-Nebro⁷, ¹Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, ²IBIMA Plataforma BIONAND, Cordoba, Spain, ³IBIMA Plataforma BIONAND, Málaga, Spain, ⁴IBIMA, Málaga, Spain, ⁵Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁷Hospital Regional Universitario de Málaga, Malaga, Spain
Background/Purpose: Gut microbiota has been related to rheumatoid arthritis (RA), inflammation, and it's severity. Interstitial lung disease (ILD) is the most frequent non-pleural pulmonary manifestation…
Abstract Number: 2210 • ACR Convergence 2023
Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis
Pieter Ruytinx¹, Elien Luyten¹, Ann-Sophie De Craemer², Filip Van den Bosch³, Dirk Elewaut⁴ and Veerle Somers¹, ¹Biomedical Research Institute, Hasselt University, Department of Immunology and Infection, Diepenbeek, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, an axSpA cDNA phage display library, constructed from…
Abstract Number: 2361 • ACR Convergence 2023
Optimal Combination of Circulating Biomarkers for Predicting the Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis
Keina Yomono¹, Dinesh Khanna² and Masataka Kuwana³, ¹Nippon Medical School University, Tokyo, Japan, ²University of Michigan, Ann Arbor, MI, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: In patients with systemic sclerosis (SSc), progression of interstitial lung disease (ILD) is associated with an increased mortality. Since the course of SSc-ILD is…
Abstract Number: 2518 • ACR Convergence 2023
Could the Adenosine Pathway Identify Cases with a Progressive Fibrosing Phenotype Between Patients with Autoimmune Interstitial Lung Disease? An Initial Approach
Olga Sanchez Pernaute¹, Cristina Vadillo-Font², Hilda Godoy³, Laura Cebrian⁴, Gema Bonilla⁵, Rosario Garcia-Vicuna⁶, Irene Llorente Cubas⁶, Fredeswinda Romero¹, Rosalía Laporta³, Belen Lopez-Muñiz⁴, M Asunción Nieto⁷, Luis Gomez-Carrera⁵, Claudia Valenzuela⁸, M Jesus Rodriguez-Nieto⁹ and lydia Abasolo¹⁰, ¹IIS-HU Fundación Jiménez Díaz, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴Hospital Universitario Infanta Leonor, Madrid, Spain, ⁵Hospital Univ. La Paz, Madrid, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷Hospital Clínico S. Carlos, Madrid, Spain, ⁸Hospital Universitario La Princesa, Madrid, Spain, ⁹Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ¹⁰Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Interstitial lung diseases with an autoimmune background (AIP) are a heterogeneous group of processes. There is an unmet need to identify those cases with…
Abstract Number: 0029 • ACR Convergence 2023
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts
Nozima Aripova¹, Michael Duryee¹, Carlos Hunter¹, Breanna Butler¹, Amy Nelson¹, Bryant England¹, James O'Dell¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cellular interactions between alveolar macrophages (MΦ) and human lung fibroblasts (HLFs) contribute to excessive pro-inflammatory and pro-fibrotic responses in rheumatoid arthritis interstitial lung disease…
Abstract Number: 0402 • ACR Convergence 2023
Automated Detection and Quantification of Hand Joint Swelling in Rheumatoid Arthritis: Computer Vision, Deep Neural Network Models, and a Potential Biomarker for Disease Activity Monitoring
Marc Blanchard¹, Jules Maglione², Cinja Koller³, Patrick Hermann⁴, David Brüschweiler³, Arnd Kleyer⁵ and Thomas Hügle⁶, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²EPFL, Lausanne, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴ATREON SA, Lausanne, Switzerland, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: We have previously shown that automated detection and processing of dorsal finger fold patterns from hand photographs can be used as a digital biomarker…
Abstract Number: 0578 • ACR Convergence 2023
Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis
Meghan Anderson¹, Cynthia Magro² and H Michael Belmont³, ¹New York University, New York, NY, ²Weill Cornell Medicine, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Tissue damage in LN is mediated by immune complex activation of the classic complement pathway (PMID 23929771). In a study of LN, renal C5b-9…
Abstract Number: 0822 • ACR Convergence 2023
From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes
Monica Hannani¹, Zofia Lisowska-Petersen², Morten Karsdal², Cecilie Bager², Anne-Christine Bay-Jensen² and Christian Thudium², ¹University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) is a diverse and multifaceted condition. Despite its widespread incidence, the core mechanisms of the disease remain elusive, and therapeutic interventions are…
Abstract Number: 1124 • ACR Convergence 2023
A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China
Charles Jones¹, Jianzhong Zhang², Lihua Wang³, Xunyi Dai⁴, Huimin Wang⁵, Xiadong Bi⁶, Xinsuo Duan⁷, Zudong Meng⁸, Zhongwei Tian⁹, Aie Xu¹⁰, Bin Yang¹¹, Shuping Guo¹², Wei Li¹³, Qingchun Diao¹⁴, Hong Fang¹⁵, Yongjun Liu¹⁶, Juanli Fan¹⁷, Min Yan¹⁸, Sensen Lin¹⁹, Mingfei Zhu²⁰, xianjun Hu²⁰, Jinfeng Lin²⁰ and Mingye Bi²¹, ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University People’s Hospital, Beijing, China, ³Jinan Central Hospital, Jinan, China, ⁴Wuxi Second People's Hospital, Wuxi, China, ⁵Jinzhong First People's Hospital, Jinzhong, China, ⁶Nanyang First People's Hospital, Nanyang, China, ⁷Chengde Medical College Affiliated Hospital, Chengde, China, ⁸Shiyan City People's Hospital, Shiyan, China, ⁹The First Affiliated Hospital of Xinxiang Medical College, Weihui, China, ¹⁰Hangzhou Third People's Hospital, Hangzhou, China, ¹¹Skin Disease Hospital of Southern Medical University, Guangzhou, China, ¹²The First Hospital of Shanxi Medical University, Taiyuan, China, ¹³West China Hospital of Sichuan University, Chengdu, China, ¹⁴Chongqing Traditional Chinese Medicine Hospital, Chongqing, China, ¹⁵The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁶Qiqihar Traditional Chinese Medicine Hospital, Qiqihar, China, ¹⁷Yuncheng Central Hospital, Yuncheng, China, ¹⁸Shengli Oilfield Central Hospital, Dongying, China, ¹⁹Hangzhou Tigermed, Hangzhou, China, ²⁰Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²¹Wuxi People's Hospital, Wuxi, China
Background/Purpose: Hemay005 is an orally active selective PDE4 inhibitor under clinical development for treating chronic inflammatory diseases. Hemay005 significantly inhibits the activation of T lymphocytes,…
Abstract Number: 1320 • ACR Convergence 2023
Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept
Paolo Semeraro¹, Fabrizio Angeli¹, Alessia Caproli¹, Franco Franceschini², Paolo Airò³ and Silvia Piantoni⁴, ¹Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁴ASST Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Helper T cells (Th) are key players in rheumatoid arthritis (RA). Th17 and Th17.1 have a prominent function in the early phase of inflammation,…
Abstract Number: 1638 • ACR Convergence 2023
CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden
Tuyet-Hang Pham¹, Michael A. Smith¹, Nannette Mittereder¹, William A. Rees², Ilias Alevizos², E. William St. Clair³ and Claire Emson¹, ¹Horizon Therapeutics plc, Rockville, MD, ²Horizon Therapeutics, Rockville, MD, ³Duke University Medical Center, Durham, NC
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 1780 • ACR Convergence 2023
Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova², Lucia Ondrejcakova³, Vladimir Cervenak⁴, Monika Gregova⁵, Sarka Forejtova⁵, Jana Horinkova¹, Jindriska Gatterova⁶, Michal Tomcik⁷, Jiri Vencovsky⁷, Karel Pavelka⁸ and Ladislav Senolt⁹, ¹Institute of Rheumatology, Prague, Czech Republic, ²First faculty of medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Department of Medical Imaging, St Anne's University Hospital, and Faculty of Medicine, Masaryk University, Brno, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ⁶Rheumatology Institute, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Axial spondyloarthritis (AxSpA) is a frequent inflammatory disease with a significant impact on a patient's quality of life. Therefore, early diagnosis and recognition of…
Abstract Number: 2218 • ACR Convergence 2023
Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients
John Koussiouris¹, Nikita Looby¹, Max Kotlyar², Vathany Kulasingam³, Igor Jurisica⁴, Ashish J Mathew⁵, Proton Rahman⁶ and Vinod Chandran⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁵Christian Medical College, Vellore, India, ⁶Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The use of biologic disease-modifying anti-rheumatic drugs (bDMARDS) is the current standard of care for severe diseases like psoriatic arthritis (PsA) which affects approximately…
Abstract Number: 2362 • ACR Convergence 2023
Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients
Thierry Sornasse¹, Vishal Kakkar², Rebecca Ross³, Sunhwa Kim⁴ and Francesco Del Galdo⁵, ¹AbbVie, Inc., North Chicago, IL, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Inc., South San Francisco, CA, ⁵University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].